ENVB Enveric Biosciences, Inc. Stock Quote

ENVB [NASD]

Index	-	P/E	-	EPS (ttm)	-76.19	Insider Own	15.01%	Shs Outstand	1.06M	Perf Week	-7.85%
Market Cap	7.09M	Forward P/E	-	EPS next Y	-14.00	Insider Trans	0.00%	Shs Float	0.77M	Perf Month	-18.91%
Income	-50.30M	PEG	-	EPS next Q	-3.83	Inst Own	21.10%	Short Float	21.66%	Perf Quarter	-24.02%
Sales	-	P/S	-	EPS this Y	-73.80%	Inst Trans	-2.61%	Short Ratio	0.61	Perf Half Y	-79.74%
Book/sh	1.76	P/B	3.79	EPS next Y	12.50%	ROA	-	Target Price	32.50	Perf Year	-92.81%
Cash/sh	16.98	P/C	0.39	EPS next 5Y	-	ROE	-	52W Range	5.90 - 187.00	Perf YTD	-85.61%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-96.50%	Beta	1.36
Dividend %	-	Quick Ratio	8.30	Sales past 5Y	-	Gross Margin	-	52W Low	10.78%	ATR	1.68
Employees	23	Current Ratio	8.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.54	Volatility	11.20% 19.45%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.58	Prev Close	6.69
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	271.65K	Price	6.54
Recom	2.30	SMA20	-11.31%	SMA50	-29.11%	SMA200	-77.51%	Volume	59,064	Change	-2.30%

Jul-27-22 07:30AM	Enveric Biosciences Appoints New Independent Directors Business Wire
Jul-26-22 05:30PM	Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules Business Wire -8.53%
Jul-25-22 08:00AM	Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules Business Wire -28.36%
Jul-19-22 07:30AM	Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines Business Wire
Jul-14-22 12:15PM	Enveric Biosciences Announces Reverse Stock Split Business Wire -27.63%
Jul-13-22 07:30AM	Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio Business Wire
Jun-08-22 07:30AM	Enveric Biosciences to Participate in Upcoming Conferences in June 2022 PR Newswire
May-24-22 04:05PM	Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022 PR Newswire -11.65%
May-17-22 07:30AM	Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 PR Newswire +7.13%
May-11-22 07:30AM	Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders PR Newswire -14.22%
May-05-22 07:30AM	Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET PR Newswire -5.61%
May-03-22 05:13PM	Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock PR Newswire
Apr-29-22 08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing GlobeNewswire
Apr-25-22 08:35AM	KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th GlobeNewswire
Apr-06-22 07:30AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022 PR Newswire
Mar-31-22 05:02PM	Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update PR Newswire -7.61%
Mar-29-22 07:30AM	Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application PR Newswire +5.79%
Mar-15-22 07:30AM	Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates PR Newswire +7.00%
Mar-03-22 07:30AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022 PR Newswire
Mar-01-22 07:30AM	Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules PR Newswire +12.93%
Feb-17-22 07:30AM	Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress PR Newswire
Feb-15-22 04:05PM	Enveric Biosciences Announces Closing of $10 Million Public Offering PR Newswire -5.23%
Feb-11-22 08:30AM	Enveric Biosciences Announces Pricing of $10 Million Public Offering PR Newswire -49.03%
Feb-08-22 04:45PM	Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis IPO-Edge.com
07:30AM	Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate PR Newswire
Jan-18-22 07:30AM	Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders PR Newswire -7.57%
Jan-06-22 04:01PM	Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022 PR Newswire -6.27%
Dec-06-21 07:30AM	Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer PR Newswire
Nov-29-21 07:30AM	Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th PR Newswire
Nov-18-21 07:30AM	Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate PR Newswire -5.26%
Nov-09-21 07:09AM	Cannabis Sector Weekly Roundup Market Exclusive
Nov-08-21 07:30AM	Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF PR Newswire
07:30AM	Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF CNW Group
Oct-26-21 07:30AM	Enveric Biosciences to Participate in Wonderland: Miami Conference PR Newswire
Oct-18-21 08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing PR Newswire
08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing CNW Group
Oct-15-21 12:52PM	Enveric Biosciences on the Merger with MagicMed Exec Edge
Oct-11-21 09:25AM	KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th CNW Group
Oct-07-21 07:30AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021 PR Newswire
Oct-05-21 07:30AM	Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds PR Newswire
Sep-20-21 07:00AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021 PR Newswire
Sep-17-21 07:00AM	Enveric Biosciences Announces Closing of MagicMed Industries Acquisition PR Newswire -8.09%
Sep-09-21 07:30AM	Enveric Biosciences Announces MagicMed Industries' Presentations at the Following Investor Conferences in September PR Newswire +15.13%
Aug-18-21 08:00AM	Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders PR Newswire
Aug-02-21 07:00AM	New CBD Trials Point the Way for Enveric, MagicMed Newsfile
Jul-08-21 08:00AM	Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma PR Newswire +10.10%
Jun-28-21 09:00AM	SHAREHOLDER ALERT: Halper Sadeh LLP Investigates ARPO, ALTA, ENVB, FBNC, MCF; Shareholders are Encouraged to Contact the Firm PR Newswire +19.82%
Jun-25-21 09:00PM	SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Enveric Biosciences, Inc. - ENVB PR Newswire
05:58PM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Enveric Biosciences, Inc. Merger GlobeNewswire
Jun-07-21 07:00AM	CEO Presenting on the Emerging Growth Conference on June 9. Register here GlobeNewswire +12.71%
Jun-05-21 06:12PM	SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CNST, FMBI, SWN, ENVB, MLND; Shareholders are Encouraged to Contact the Firm PR Newswire
Jun-04-21 07:00PM	Lifshitz Law Firm, P.C. Announces Investigation of CLDR, DTRCD, DCRN, ENVB, PACX, SNX, XERS, and SBBP PR Newswire
Jun-03-21 09:00AM	Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences PR Newswire
Jun-02-21 10:00AM	INVESTIGATION ALERT: Halper Sadeh LLP Investigates CLDR, FMBI, ENVB, HRVSF; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Jun-01-21 06:57PM	ENVERIC BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Enveric Biosciences, Inc. - ENVB Business Wire +6.73%
10:37AM	Enveric Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Enveric Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ENVB Business Wire
May-24-21 06:00AM	Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives PR Newswire -8.09%
May-18-21 07:30AM	Enveric Biosciences Reports First Quarter 2021 Financial Results PR Newswire +8.74%
May-12-21 07:30AM	Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board PR Newswire
Apr-19-21 09:00AM	Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021 ACCESSWIRE
Apr-14-21 07:30AM	Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st ACCESSWIRE
Apr-12-21 07:30AM	Enveric Biosciences Appoints Carter Ward as Chief Financial Officer PR Newswire -6.45%
Apr-01-21 08:01AM	Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021 PR Newswire
Mar-18-21 08:00AM	Enveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors PR Newswire
Mar-17-21 11:00AM	Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network ACCESSWIRE
Mar-16-21 08:21AM	Diverse Biotech announces Strategic Transaction with Enveric Biosciences PR Newswire
Mar-15-21 08:00AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in March PR Newswire
Mar-10-21 12:34PM	CBD-focused Enveric Biosciences stock soars on heavy volume after license deal with cancer treatment company MarketWatch +54.95%
08:00AM	Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech PR Newswire
Feb-25-21 07:00AM	Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs PR Newswire
Feb-12-21 08:30AM	Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock PR Newswire -5.13%
Feb-09-21 09:27AM	Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering PR Newswire
Jan-21-21 10:35AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-19-21 08:30AM	Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies PR Newswire
Jan-15-21 04:01PM	Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering PR Newswire -5.04%
Jan-12-21 09:00AM	Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire -13.35%
Jan-05-21 08:30AM	Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors PR Newswire

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience